Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III
This article was originally published in PharmAsia News
Executive Summary
The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars.
You may also be interested in...
Biosimilar Pathway Quickly Becoming Crowded In U.S.
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Need a specific report? 1000+ reports available
Buy Reports